| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/24/2011 | CA2493026C Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines |
| 05/24/2011 | CA2491701C Fredericamycin derivatives as drugs for tumor treatment |
| 05/24/2011 | CA2477601C 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| 05/24/2011 | CA2472821C Process for producing fused imidazole compound, and reformatsky reagent in stable form and process for producing the same |
| 05/24/2011 | CA2463626C Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 05/24/2011 | CA2452408C Method and apparatus for the photomodulation of living cells |
| 05/24/2011 | CA2443952C Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| 05/24/2011 | CA2439787C Nitrogen-based camptothecin derivatives |
| 05/24/2011 | CA2401604C Method of treating cancer with anti-neurotrophin agents |
| 05/24/2011 | CA2393710C Caspase inhibitors and uses thereof |
| 05/24/2011 | CA2385266C Novel cell cycle checkpoint genes and proteins encoded thereby |
| 05/24/2011 | CA2384378C Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 05/24/2011 | CA2366090C Composition and method for inducing apoptosis in prostate cancer cells |
| 05/24/2011 | CA2360382C Use of antibodies for the vaccination against cancer |
| 05/24/2011 | CA2345277C Methods for isolation, quantification, characterization and modulation of antigen-specific t cells |
| 05/24/2011 | CA2342064C Long wave length absorbing bacteriochlorin alkyl ether analogs |
| 05/24/2011 | CA2341642C Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor |
| 05/24/2011 | CA2341507C Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them |
| 05/24/2011 | CA2338751C Cancer cells from body fluids containing cells, isolation thereof and agents containing the same |
| 05/24/2011 | CA2303428C .alpha.-ketoamide multicatalytic protease inhibitors |
| 05/24/2011 | CA2229631C Gene therapy using ovine adenoviral vectors |
| 05/24/2011 | CA2211687C Vascular endothelial growth factor-b |
| 05/19/2011 | WO2011060260A2 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
| 05/19/2011 | WO2011060215A1 Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer |
| 05/19/2011 | WO2011060179A1 Use of peptide epoxyketones for metastasis suppression |
| 05/19/2011 | WO2011060112A1 Deuterated tyrosine kinase inhibitors |
| 05/19/2011 | WO2011059388A1 Oxazolo[4,5-c]pyridine substituted pyrazine |
| 05/19/2011 | WO2011059121A1 Salinomycin/inorganic-hydroxide nanohybrid material, pharmaceutical composition including same, and cancer treatment method using same |
| 05/19/2011 | WO2011059021A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative |
| 05/19/2011 | WO2011058943A1 Pharmaceutical composition formed from combining compound having mch r1 antagonist activity and compound having npy y5 antagonist activity |
| 05/19/2011 | WO2011058905A1 Nitrobenzene derivative, highly-reactive-ros-generating agent using same, and method for generating highly-reactive ros |
| 05/19/2011 | WO2011058773A1 Oil-based composition |
| 05/19/2011 | WO2011058766A1 Aryl carboxamide derivatives as ttx-s blockers |
| 05/19/2011 | WO2011058522A1 Sorafenib ethylsulfonate salt, process for preparation and use |
| 05/19/2011 | WO2011058517A1 Single-chain variable fragment (scfv) able to recognize and bind cd99 human protein |
| 05/19/2011 | WO2011058508A2 New compositions for the treatment of chemioresitant and/or potentially chemioresistant leukaemias |
| 05/19/2011 | WO2011058179A1 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide |
| 05/19/2011 | WO2011058139A1 A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| 05/19/2011 | WO2011058113A1 Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058112A1 Fused bicyclic pyrazole derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058111A1 Aminopurine derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058110A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058108A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058025A1 N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use |
| 05/19/2011 | WO2011057986A1 Homoglutamic acid derivatives |
| 05/19/2011 | WO2011057974A1 Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
| 05/19/2011 | WO2011057960A1 Crystalline cdc7 inhibitor salts |
| 05/19/2011 | WO2011057892A1 2,3-dihydrobenzoxazine and 2,3-dihydrobenzothiazine derivates as hif-inhibitors for the treatment of cancer and inflammatory diseases |
| 05/19/2011 | WO2011057806A1 Tubulin inhibitors |
| 05/19/2011 | WO2011057788A1 Antibodies specific for claudin 6 (cldn6) |
| 05/19/2011 | WO2011057784A1 Compounds for pim kinase inhibition and for treating malignancy |
| 05/19/2011 | WO2011057709A1 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents |
| 05/19/2011 | WO2011057504A1 Use of variable lymphocyte receptor (vlr) of agnatha in medicament preparation |
| 05/19/2011 | WO2011057477A1 Tetrapeptide analogs, preparation method and use thereof |
| 05/19/2011 | WO2011057471A1 Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor |
| 05/19/2011 | WO2011057437A1 Anti-epidemic growth factor receptor antibody and encoding genes and uses thereof |
| 05/19/2011 | WO2011057436A1 Anti-epidermal growth factor receptor antibodies and uses thereof |
| 05/19/2011 | WO2011057435A1 Anti-epidermal growth factor receptor antibodies and uses thereof |
| 05/19/2011 | WO2011036561A3 Process |
| 05/19/2011 | WO2011036305A3 Pdgfrbeta inhibitors for use in the treatment of t-cell lymphoma |
| 05/19/2011 | WO2011029775A8 [1,2,4]triazolo [1,5-c]pyrimidine derivatives as hsp90 modulators |
| 05/19/2011 | WO2011003065A3 Pyrazolopyrimidine jak inhibitor compounds and methods |
| 05/19/2011 | WO2011002852A3 Pro-drug complexes and related methods of use |
| 05/19/2011 | WO2010151074A3 Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy |
| 05/19/2011 | WO2010151073A3 Conjugates of anticancer chemotherapeutic agent-chlorine derivatives, photosensitizer containing same and composition for treating cancer containing same |
| 05/19/2011 | WO2010151005A3 Injectable composition containing hydroxychloroquine for local administration for treating cancer |
| 05/19/2011 | WO2010136000A4 Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them |
| 05/19/2011 | WO2010128087A9 Uses of immunoconjugates targeting cd138 |
| 05/19/2011 | WO2010111634A3 Renin inhibitors |
| 05/19/2011 | US20110118825 Anti-angiogenic compositions and methods of use |
| 05/19/2011 | US20110118528 Methods and Nutritional Formulations to Increase the Efficacy and Reduce the Side Effects of Cancer Treatment |
| 05/19/2011 | US20110118470 Nitrogen-containing aromatic derivatives |
| 05/19/2011 | US20110118445 Inhibitor protein of the wnt signal pathway |
| 05/19/2011 | US20110118343 Antitumoral Macrolides |
| 05/19/2011 | US20110118342 Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| 05/19/2011 | US20110118339 Chemically modified oligonucleotides and uses thereof |
| 05/19/2011 | US20110118337 Method of Using Compositions Comprising MIR-192 and/or MIR-215 for the Treatment of Cancer |
| 05/19/2011 | US20110118336 Microrna-21 antagonists and its target PDCD4 for use in the treatment of a glioma |
| 05/19/2011 | US20110118327 In vivo assessment of toxicity and pharmacokinetics of methylglyoxal |
| 05/19/2011 | US20110118323 Macrocyclic compounds and methods of treatment |
| 05/19/2011 | US20110118320 Substituted pyrroles and methods of use |
| 05/19/2011 | US20110118309 Use of hdac inhibitors for the treatment of hodgkin's disease |
| 05/19/2011 | US20110118305 Compounds |
| 05/19/2011 | US20110118298 Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| 05/19/2011 | US20110118297 Tivozanib and Temsirolimus in Combination |
| 05/19/2011 | US20110118296 Bis-Carbazole DNA Intercalating Agents for Antitumor Therapy |
| 05/19/2011 | US20110118291 Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
| 05/19/2011 | US20110118287 Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof |
| 05/19/2011 | US20110118285 Heterocycles as protein kinase inhibitors |
| 05/19/2011 | US20110118284 Thienopyrimidine compounds |
| 05/19/2011 | US20110118283 Substituted Pyrrolidine-2-Carboxamides |
| 05/19/2011 | US20110118278 Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs |
| 05/19/2011 | US20110118275 OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE |
| 05/19/2011 | US20110118274 Proteasome inhibitors and their use in treating pathogen infection and cancer |
| 05/19/2011 | US20110118271 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases |
| 05/19/2011 | US20110118258 Quinazolin-oxime derivatives as hsp90 inhibitors |
| 05/19/2011 | US20110118257 Novel kinase modulators |
| 05/19/2011 | US20110118255 PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS |
| 05/19/2011 | US20110118252 Substituted amide derivatives and methods of use |
| 05/19/2011 | US20110118248 Heteroaryl sulfonamides and CCR2/CCR9 |